A Study of CDX-585 in Patients With Advanced Malignancies
Completed · Phase 1
Conditions studied: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
In brief
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Key facts
- Study ID
- NCT05788484
- Run by
- Celldex Therapeutics
- People needed
- 20
- Starts
- 2023-05-11
- Expected to finish
- 2025-05-21
- Last updated by the study team
- 2025-06-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- George Washington University Cancer Center — Washington D.C., District of Columbia, United States
- AdventHealth Celebration — Celebration, Florida, United States
- Perlmutter Cancer Center at NYU Langone Health — New York, New York, United States
- Providence Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.